Supported by a grant from The Michael J. Fox Foundation for Parkinson’s Research, the trial will assess the safety, tolerability, and pharmacokinetics of both single and multiple doses of orally administered HL192 in healthy individuals aged 18 to 80 years. Initial results of the study are expected to be announced in the second half of 2024.
First-In-Human Trial of Nurr1 Activator H... - Cure Parkinson's
First-In-Human Trial of Nurr1 Activator HL192 in Parkinson Disease Initiated
Written by
Farooqji
To view profiles and participate in discussions please or .
1 Reply
•
I can see a clinical trial being done in Quebec, Canada and do not see other listed locations for the trial
Not what you're looking for?
You may also like...
Parkinson's Disease Clinical trial for First in Humans use of FGF-1 to treat Parkinson's Disease started by Zhittya Genesis Medicine.
start the First in Humans Proof of Concept-Phase I clinical trial to treat Parkinson's. Daniel...
BlueRock the first company to report initial success treating Parkinson's disease in humans using an experimental stem cell therapy
com/business/healthcare-pharmaceuticals/bayer-phase-i-trial-results-parkinsons-cell-therapy-positive
Monkeys Aren't Human and Animal \"Models\" of Parkinson's Disease Aren't Actually Parkinson's Disease, BUT This Stem Cell Trial Offers Hope!
signs in monkeys modeling Parkinson’s disease, paving the way for trials in human patients....
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial
https://www.sciencealert.com/parkinsons-drug-reduces-disease-markers-in-breakthrough-trial
Related Posts
ACTIVE-ASSISTED CYCLING improves tremor and bradykinesia in Parkinson's disease.
MSC clinical trials to treat Parkinson's disease- First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's
Vascular Dysfunction in the Brain as an Initiating Event in Parkinson’s Disease
Vibrating Gloves for Parkinson's Disease
